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Abstract
Rationale—The interoceptive and reinforcing effects of 3,4-methylenedioxymethamphetamine
(MDMA) are similar to those of psychostimulants, but the role of dopamine in the behavioral
effects of MDMA is not well documented, especially in primates.
Objective—The aim of this study was to assess the role of dopamine in the behavioral effects of
MDMA in two nonhuman primate species.
Methods—The behavioral effects of MDMA, with and without serotonergic or dopaminergic
pretreatments, were studied in squirrel monkeys trained to respond under a fixed-interval schedule
of stimulus termination; effects on caudate dopamine levels were studied in a separate group of
squirrel monkeys using in vivo microdialysis. Positron emission tomography neuroimaging with
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the dopamine transporter (DAT) ligand [18F]FECNT was used to determine DAT occupancy by
MDMA in rhesus monkeys.
Results—MDMA (0.5–1.5 mg/kg) did not induce behavioral stimulant effects, but the highest
dose of MDMA suppressed responding. Pretreatment with fluoxetine (3.0 mg/kg) or the selective
5HT2A antagonist M100907 (0.03–0.3 mg/kg) attenuated the rate suppressing effects of MDMA.
In contrast, pretreatment with the selective dopamine transporter inhibitor RTI-177 (0.1 mg/kg)
did not alter the rate suppressing effects of MDMA. Administration of MDMA at a dose that
suppressed operant behavior had negligible effects on extracellular dopamine. The percent DAT
occupancy of MDMA at a dose that suppressed operant behavior also was marginal and reflected
low in vivo potency for DAT binding.
Conclusions—Collectively, these results indicate that behaviorally relevant doses of MDMA do
not induce behavioral stimulant or dopamine transporter-mediated effects in nonhuman primates.
Keywords
MDMA; PET neuroimaging; Microdialysis; Dopamine; Serotonin; Operant behavior Nonhuman
primates
Introduction
3,4-Methylenedioxymethamphetamine (MDMA) is a substituted phenethylamine with
chemical similarities to mescaline-type hallucinogens and amphetamine-type
psychostimulants. Studies investigating the behavioral pharmacology of MDMA have
typically focused on serotonergic mechanisms (Bankson and Cunningham 2001; Bankson
and Cunningham 2002), but more recently, dopaminergic mechanisms have been
investigated. In rodents, MDMA has been shown to increase synaptic dopamine via
interactions with the dopamine transporter (Iravani et al. 2000; White et al. 1996; Nash and
Brodkin 1991; Yamamoto and Spanos 1988; Baumann et al. 2004). In behavioral studies,
MDMA self-administration and MDMA-induced locomotor stimulation were attenuated in
rats pretreated with the D1-like antagonist SCH 23390 (Daniela et al. 2004). Similarly,
MDMA-elicited hyper-locomotion was strongly correlated with elevations in extracellular
DA in nucleus accumbens, striatum, and prefrontal cortex in the rat (Baumann et al. 2008).
The pharmacological basis for this correlation may involve interactions of DA released
following MDMA administration, as S(+)-MDMA-stimulated locomotor activity is
dependent on D1 and D2 receptor activation, and D1 receptors also appear to play a role in
the discriminative stimulus properties of (+)-MDMA (Bubar et al. 2004). On a more
molecular level, MDMA-induced ERK phosphorylation within the nucleus accumbens was
blocked by the D1-like antagonist SCH 39166, but not by the D2-like antagonist raclopride
(Acquas et al. 2007). A more complex role for dopaminergic systems in the locomotor
stimulant effects of MDMA has been described in the mouse (Risbrough et al. 2006).
In primates, however, the role of dopaminergic mechanisms in the behavioral effects of
MDMA has not been intensively investigated. Nevertheless, in rhesus monkeys trained to
discriminate amphetamine from saline, MDMA dose-dependently and fully substituted for
the amphetamine cue (Kamien et al. 1986). Similarly, MDMA exhibits amphetamine-like
discriminative stimulus and subjective effects in humans (Peroutka et al. 1988; Tancer and
Johanson 2001, 2007; Johanson et al. 2006). No previous studies have used selective
antagonists to attempt to ascertain the neuropharmacological underpinnings of the
discriminative stimulus effects of MDMA in human or nonhuman primates. Furthermore,
while MDMA is self-administered by rhesus monkeys (Beardsley et al. 1986; Fantegrossi et
al. 2002; Lamb and Griffiths 1987; Lile et al. 2005; Wang and Woolverton 2007), it is
usually done so to a lesser extent than traditional psychostimulants such as cocaine or
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methamphetamine. Importantly, administration of 5-HT2 antagonists (selective and
nonselective) suggests that the reinforcing effects of MDMA are mediated through central
serotonergic systems in rhesus monkeys (Fantegrossi et al. 2002). Analogous studies using
dopamine antagonists have not yet been undertaken in primates. Thus, the interoceptive and
reinforcing effects of MDMA in primates are consistent with those of other dopaminergic
drugs, although serotonergic mechanisms of action are much more pronounced. The
behavioral profile of MDMA is thus not easily defined as stimulant-like in nonhuman
primates, and the effects of MDMA on motor activity in nonhuman primates do not conform
to those demonstrated in rodents. For example, MDMA did not alter spontaneous home cage
activity in rhesus monkeys, although administration of methamphetamine to these same
animals reliably increased motor behavior (Crean et al. 2006). Taffe and colleagues have
reported that MDMA-treated rhesus monkeys appeared drug intoxicated but otherwise were
normally responsive without evidence of repetitive stereotyped movement (Taffe et al.
2006). This description does not contradict our own observations of reduced motor activity,
closed eyes, and a blunted responsiveness to environmental stimuli in squirrel monkeys
following MDMA administration. The contrast between what is observed in rodents and
nonhuman primates is indeed striking.
Accordingly, the present studies were designed to assess directly the role of dopaminergic
systems in the behavioral effects of MDMA in two nonhuman primate species. The
behavioral effects of MDMA were studied in squirrel monkeys (Saimiri sciureus) trained to
respond in an operant procedure that is especially sensitive to increases in response rates
induced by various dopaminergics drugs (Kimmel et al. 2007). The effects on caudate
dopamine levels of doses at least as high as those found to be active in the behavioral
procedure were studied in a separate group of squirrel monkeys using in vivo microdialysis.
Lastly, positron emission tomography (PET) neuroimaging with the dopamine transporter
(DAT) ligand [18F]FECNT was used to determine DAT occupancy by a challenge injection
of MDMA in rhesus monkeys (Macaca mulatta). Collectively, the results indicate that
behaviorally relevant doses of MDMA do not induce behavioral stimulant or dopamine
transporter-mediated effects in nonhuman primates.
Materials and methods
Subjects
Eight adult male squirrel monkeys weighing 800–1,150 g served as subjects in behavioral
(N=6) and neurochemical (N=2) studies. Three adult rhesus monkeys (two female, one male)
weighing between 7.8 and 13.4 kg served as subjects in PET neuroimaging experiments. All
animals lived in individual stainless steel home cages and were provided daily access to
food (Harlan Teklad monkey chow; Harlan Teklad, Madision, WI, USA; fresh fruit and
vegetables) and unlimited water. Environmental enrichment devices were provided on a
regular rotating basis. All monkeys had prior exposure to cocaine and other drugs with
selective dopaminergic or serotonergic activity in various behavioral studies. Animal use
procedures were in strict accordance with the National Institutes of Health “Guide for Care
and Use of Laboratory Animals” (Publication No. 85-23, revised 1985) and were approved
by the Institutional Animal Care and Use Committee of Emory University.
Procedures
Effects of MDMA on schedule-controlled behavior in squirrel monkeys—
During daily test sessions, squirrel monkeys (s-170, s-171, s-177, s-187, s-189, s-195) used
in behavioral studies were seated in Plexiglas chairs equipped with stimulus lights, a
response lever, and equipment for delivering a mild electrical stimulus to the tail. Behavioral
test sessions lasted 90-min each day and occurred within ventilated, sound-attenuating
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chambers (MED Associates, Georgia, VT, USA). All animals were trained under a fixed-
interval (FI) 300-s schedule of stimulus termination. At the beginning of each testing
session, the behavioral chamber was illuminated with a red light for 300 s. At the end of this
interval, monkeys were required to press the lever once within 3 s to terminate the red light,
which was associated with an impending electrical stimulus. Upon termination of the red
light, a white light was illuminated for 15 s, followed by a 60-s timeout. If the lever was not
pressed during the 3-s limited hold period, the animal received a 200-ms 3-mA stimulus to
the tail, followed by a 60-s timeout. Responding during timeout periods had no scheduled
consequences. Animals were tested each day, 5 days/week, and each daily session consisted
of 15 consecutive FI components.
Drug experiments began when rates and patterns of responding stabilized (less than 20%
variability in response rates for five consecutive test sessions). Drugs were administered on
Tuesdays and Fridays and saline was administered on Thursdays as a control. A single dose
of drug (MDMA or methamphetamine) or saline was administered i.m. 5 s before the
beginning of the experimental session. In drug interaction experiments, a dose of the
selective serotonin transporter (SERT) inhibitor, fluoxetine, the 5HT2A receptor antagonist,
M100907, or the selective DAT inhibitor, RTI-177, was administered i.m. 15 min pre-
session. Subjects s-170, s-171, s-177, and s-187 received methamphetamine, MDMA,
fluoxetine and M100907. Subjects s-170, s-187, s-189 and s-195 received MDMA and
RTI-177. Drug interaction experiments were conducted first with fluoxetine followed by
M100907 and RTI-177. Drug doses were administered in a quasi-random order and each
dose or drug combination was determined twice. Response rate maintained by the FI 300-s
schedule of stimulus termination was computed separately for each FI component by
dividing the total number of responses in a component by the total time the red light was
present. Mean control rate was determined for each monkey by averaging response rate for
all saline (control) sessions. Data are presented for the group of monkeys as the mean
response rate ± SEM during all sessions for a particular drug condition and are expressed as
a percent of control rate obtained when saline was administered.
Guide cannula implantation—A stereotaxic apparatus was used to implant CMA/11
guide cannulae (CMA/Microdialysis, Acton, MA, USA) bilaterally to target both caudate
nuclei in two squirrel monkeys (s-165, s-175) as described previously (Czoty et al. 2000).
Anesthesia was initiated with Telazol (tiletamine hydrochloride and zolazepam
hydrochloride, 3.0 mg) and atropine. Inhaled isoflurane (1.0–2.0%) was administered to
maintain depth of anesthesia during the procedure. A stainless steel stylet was placed in the
guide cannula when not in use. Analgesics [Banamine (flunixin meglumine)] and antibiotics
[Rocephin (ceftriaxone)] were prescribed as necessary by veterinary staff. Animals were
closely monitored during recovery from anesthesia, and a minimum of 2 weeks was allowed
before microdialysis experiments were performed. The guide cannulae provided a very
specific path for the insertion of the probe such that the correct placement of the guide
ensured correct placement of the probe.
In vivo microdialysis—Microdialysis experiments were conducted in squirrel monkeys
seated in a Plexiglas chair and fitted with an adjustable Lexan neckplate that was positioned
perpendicular to the medial plane of the body just above the shoulder. All squirrel monkeys
had been acclimated to the chairs over several months. CMA/11 dialysis probes with a shaft
length of 14 mm and active dialysis membrane measuring 4 mm long and 0.24 mm diameter
were flushed with artificial cerebrospinal fluid (1.0 mM Na2HPO4, 150 mM NaCl, 3 mM
KCl, 1.3 mM Ca Cl2, 1.0 mM mg Cl2, and 0.15 mM ascorbic acid, final pH=7.4–7.56) for at
least 20 min. Probes were inserted into the guide cannulae and connected to a Harvard
PicoPlus microinfusion pump via FEP Teflon tubing. Probes were perfused with artificial
cerebrospinal fluid at a rate of 2.0µl/min for the duration of the experiment. Continuous
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samples were collected every 10 min in microcentrifuge tubes and immediately refrigerated.
Following a 60-min equilibration, three consecutive 10-min samples were collected for
determination of baseline dopamine concentration. Following collection of baseline samples,
a dose of MDMA was administered IM and 10-min samples were collected for an additional
120 min. Both subjects received 1.5 mg/kg first followed by 3.0 mg/kg at least 2 weeks
later. Finally, to assess voltage dependency of dopamine release and tissue integrity, aCSF
with a high concentration of KCl (75 mM) was perfused through the probe and dialysate was
collected for a 10-min period. A robust increase in extracellular dopamine in response to
high KCl verified tissue integrity. Animals were tested a maximum of one time per week,
and each site was accessed no more often than once every 2 weeks. This regimen of repeated
access of the caudate has produced consistent responses to drug treatment without
significant gliosis (Czoty et al. 2000).
High-performance liquid chromatography (HPLC) and electrochemical detection were used
to quantify levels of dopamine. The HPLC system consisted of a small bore (3.2 mm × 150
mm, 3µm) column (ESA, Inc., Chelmsford, MA, USA) with a commercially available
mobile phase (MD-TM, ESA, Inc.) delivered by an ESA 582 solvent delivery pump at a
flow rate of 0.6 ml/min. After loading onto the refrigerated sample tray, samples (20µl) were
automatically mixed with 3µl of ascorbate oxidase, and 18µl of the mixture was injected
into the HPLC system by an ESA Model 542 autosampler. Samples were analyzed within 12
h of collection, remaining either in a refrigerator or in the refrigerated autosampler tray
during this time. Electrochemical analyses were performed using an ESA dual-channel
analytical cell (model 5040) and guard cell (model 5020, potential = 350 mV) and an ESA
Coulochem II detector. The potential of channel 1 was set to −150 mV for oxidation, while
the potential of channel 2 was set to 275 mV for reduction. A full range of dopamine
standards (1–50 nM) was analyzed both before and after each set of samples to evaluate
possible degradation of dopamine. Levels of dopamine below 0.5 nM were considered
below the limit of detection. A desktop computer collected data and chromatograms were
generated by EZChrom Elite software (version 3.1, Scientific Software, Pleasanton, CA,
USA). The chromatograms were analyzed using the EZChrom software, comparing the
experimental samples with the standards. Mean baseline dopamine concentrations for an
individual subject were defined as the mean of the three samples preceding MDMA
administration. Samples were collected from both the left and right caudate in separate
experiments. For each animal, dopamine levels from the two studies were averaged,
resulting in a single value for that animal for each experimental condition. Data are
presented for individual subjects, and the effects of MDMA are expressed as a percent of
baseline dopamine concentrations.
PET neuroimaging—PET neuroimaging was performed in rhesus monkeys (RLm-1,
RDn-2, RBp-3) at the Emory University PET Center on a Concorde microPET P4 scanner
(Concorde MicroSystems, Knoxville, TN, USA) using [18F]FECNT. During image
acquisition, vital signs were continuously monitored, and heart rate and rectal temperature
were noted every 10 min by a trained technician. On study days, subjects were immobilized
in their home cage with 4.0 mg/kg Telazol and transported to the Emory University PET
Center. Subsequently, animals were intubated and anesthesia was maintained with 1.0% to
2.0% isoflurane. Subjects were positioned in the scanner and connected to the physiological
monitoring equipment.
A 15-min transmission scan was obtained for attenuation correction, then a slow bolus of
approximately 5.0 mCi of [18F]FECNT (specific activity 1.5 Ci/µmol) was injected over 5 to
6 min at a rate of 1.0 ml/min. The PET ligand FECNT is an N-fluoroethyl nortropane
derivative that is selective for the DAT (Goodman et al. 2000), and displacement studies
with cocaine previously determined that FECNT and cocaine bind to the same site in the
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striatum and that corresponding DAT occupancy measures for cocaine are dose-dependent
(Votaw et al. 2002). Scanning began coincident with the start of radiotracer injection. The
initial acquisition was a 28-frame dynamic sequence starting with 30-s scans and ending
with 20-min scans for a total duration of 90 min. At 90 min, a single bolus dose (1.5 mg/kg)
of MDMA was injected, and a second dynamic sequence was acquired starting with 2-min
frames and ending with 5-min frames for a total duration of 3 h for both sequences.
A generalized reference tissue method was used to analyze the resulting occupancy data
(Votaw et al. 2002). All images were reconstructed with measured attenuation correction,
zoom factor 8, and Shepp-Logan reconstruction filter cut-off at 1 cycle/cm. The axial slice
thickness was 3.375 mm. All images were decay-corrected to the time of injection. Regions
of interest were manually drawn on the late images over the putamen, caudate, and
cerebellum. The regions of interest were then overlaid on all images to obtain time–activity
curves. Data were collected in two sections with the assumption that drug infusion changed
only the k3 (Bmaxkon) rate constant (i.e., MDMA competes with FECNT for binding at the
DAT and thus decreases the apparent Bmax) from ka/3 (predrug infusion) to kb/3 (postdrug
infusion). Five rate constants (R, k2, ka/3, kb/3, and k4) and the time–activity curve from the
reference region (cerebellum) were used to model the putamen and caudate time–activity
curve. In the modeling, it was assumed that the competing ligand did not affect the blood–
brain barrier parameters (flow or extraction; R or k2) or the transporter-FECNT kinetic
properties (kon, koff= k4). Thus, these parameters were kept constant over the entire
experiment. After optimization, the covariance matrix was numerically determined and used
to estimate the uncertainty in the fit values. From this, it was found that the variance in the
k3/k4 ratio is much less than the variance in either parameter alone due to their nonvanishing
covariance. Accordingly, the k3/k4 ratio was taken as a measure of DAT density. The
fraction of transporters occupied by the competing ligand was then estimated as 1–(kb/3/k4)
(ka/3/k4).
Physiological measures—During PET neuroimaging experiments, subjects were fitted
with electronic thermistor and pulse oximetry probes coupled to a computerized medical
monitor in order to continuously observe rectal temperature and heart rate, respectively.
Baseline measures were obtained by averaging three observations collected at 5 min
increments over 15 min immediately preceding injection of MDMA, while experimental
observations were determined every 5 min following MDMA infusion. For the three rhesus
monkeys studied under deep anesthesia for PET experiments, baseline rectal temperature
was 92.08±0.42°C, and baseline heart rate was 91.22±3.47 beats per min prior to MDMA
administration.
Drugs—Racemic MDMA and methamphetamine HCl and RTI-177 were supplied by the
National Institute on Drug Abuse (Research Technology Branch, Research Triangle Park,
NC, USA). Fluoxetine HCl was supplied by Eli Lilly and Company (Indianapolis, IN,
USA). M100907 was supplied as a generous gift from Kenner C. Rice, Ph.D. at the
Laboratory of Medicinal Chemistry at the NIH/NIDDK. All drugs were dissolved in
physiological saline prior to injection and doses are expressed as the salt. The purity of
MDMA was independently verified by two separate labs (the University of Utah College of
Pharmacy, Department of Pharmacology and Toxicology, Center for Human Toxicology,
and Research Triangle Institute (RTI) International) using liquid chromatography/mass
spectrometry with positive ion electrospray ionization and selected-ion monitoring (Utah)
and nuclear magnetic resonance spectroscopy (RTI). Surgical and anesthetic drugs were
purchased from commercial sources. [18F]FECNT was synthesized and radiolabeled at the
Emory University PET Center core facilities. All HPLC reagents were purchased from
commercial sources.
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In behavioral experiments, the effects of methamphetamine (0.3 mg/kg) and fluoxetine (3.0
mg/kg) were compared to saline using a repeated-measures t test. The effects of MDMA
(0.5–1.5 mg/kg), M100907 (0.01–0.3 mg/kg), and MDMA in combination with M100907
were analyzed with repeated-measures one-way ANOVA. Drug time course data comparing
the effects of MDMA (1.5 mg/kg) alone to MDMA in combination with fluoxetine,
M100907, and RTI-177 were analyzed with repeated-measures two-way ANOVA. In
microdialysis experiments, the equal variance test failed so the effects of MDMA were
analyzed with Friedman repeated-measures ANOVA on ranks. In physiological
experiments, the effects of MDMA were analyzed with repeatedmeasures one-way
ANOVA. Significant (p<0.05) main effects were followed with Dunnett’s post hoc analyses
corrected for multiple comparisons.
Results
Schedule-controlled behavior in squirrel monkeys
Responding during nondrug sessions or following saline administration was characteristic of
typical performance maintained by FI schedules of reinforcement in squirrel monkeys.
Response rate was low early in the interval and increased as the interval elapsed. All
subjects terminated most stimuli, and electric stimulus presentation was infrequent. Mean
response rate for the group of six subjects during saline control sessions (n>10) was
0.74±0.32 responses/s. Methamphetamine (0.3 mg/kg) produced a significant (p=0.024)
stimulant effect, increasing mean session response rate to over 200% of control rate (Fig.
1a). In contrast, MDMA (0.5–1.5 mg/kg) did not produce a stimulant effect over a range of
drug doses. Rather, MDMA produced a significant (p=0.009) decrease in responding, with
the highest dose decreasing mean session response rate to below 50% of control rates.
Injection of 0.5 mg/kg MDMA resulted in a pattern of responding which was virtually
identical to that observed following saline administration.
Administration of the selective SERT inhibitor, fluoxetine (3.0 mg/kg), or the selective
5HT2A antagonist, M100907 (0.03–0.3 mg/kg), alone had no significant effect on
responding (Fig. 1b). However, pretreatment with fluoxetine (3.0 mg/kg) completely
blocked the rate suppressing effects of the highest dose (1.5 mg/kg) of MDMA (Fig. 2).
Moreover, a twofold higher dose (3.0 mg/kg) of MDMA was ineffective in suppressing
response rate when administered following pretreatment with fluoxetine (data not shown).
Similarly, pretreatment with the selective 5HT2A antagonist, M100907 (0.03–0.3 mg/kg),
significantly (p=0.007) attenuated the rate suppressing effects of MDMA in a dose-
dependent manner (Fig. 2). In drug time course experiments (Fig. 3), there was a significant
main effect of fluoxetine treatment (p=0.028) and time (p= 0.029) and a significant
interaction (p=0.005, Fig. 3a). Likewise, the effect of M100907 treatment approached
significance (p=0.062) and there was a main effect of time (p=0.001, Fig. 3b). Lastly,
administration of the selective DAT inhibitor, RTI-177 (0.1 mg/kg) had a significant
(p=0.02) stimulant effect (Fig. 3c). However, pretreatment with RTI-177 had no significant
effect on MDMA-induced decreases in response rate.
In vivo microdialysis
In vivo microdialysis experiments were conducted in conscious squirrel monkeys in order to
examine the neurochemical effects of behaviorally active doses of MDMA (1.5 and 3.0 mg/
kg). In all experiments, extracellular dopamine levels stabilized within 60 min of probe
insertion. Mean basal dopamine levels unadjusted for probe recovery were 3–6 nM, as
reported previously (Czoty et al 2000, 2002). Administration of MDMA at a dose (1.5 mg/
kg) that markedly suppressed operant behavior had negligible effects on dopamine in both
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subjects (Fig. 4). A twofold higher dose (3.0 mg/kg) did effectively increase dopamine to
approximately 200% of baseline and the effect approached significance (p=0.091).
However, it is important to note that both subjects were in a semi-cataleptic state and largely
unresponsive to environmental stimuli following this highest dose. These effects were not
observed in behavioral experiments when 3.0 mg/kg MDMA was administered following
fluoxetine pretreatment. A robust increase in dopamine was always obtained during
perfusion with high KCl, verifying integrity of caudate tissue.
PET neuroimaging
Drug-induced displacement of [18F]FECNT binding in rhesus monkeys was used to
determine the percent dopamine transporter occupancy of MDMA at a dose (1.5 mg/kg) that
significantly suppressed operant behavior in squirrel monkeys. Mean percent occupancy in a
group of three subjects was 20±13% in the caudate and 12±10% in the putamen (Table 1).
Note that percent occupancy was below the limit of detection in both regions of interest in
one subject. The results reflect low in vivo potency for DAT binding. Physiological
monitoring during acquisition of PET data revealed a significant (p=0.007) increase in heart
rate with no significant effect on rectal temperature following MDMA administration (Fig.
5).
Discussion
Previous research on the persistent neurochemical effects of MDMA in rodents and
nonhuman primates generally indicates that rodents are less sensitive to monoamine
depletion following repeated MDMA administration (e.g., Slikker et al. 1988; Slikker et al.
1989; Fischer et al. 1995), but few studies have directly compared the behavioral effects of
MDMA in rodents and primates. Nevertheless, interesting differences between the in vivo
effects of MDMA in rodents and primates have been previously reported. For example,
while MDMA decreased prepulse inhibition of the startle response in rats, MDMA increased
prepulse inhibition in human subjects (Vollenweider et al. 1999). Similarly, although human
subjects rate the positive subjective effects of MDMA as higher than those of amphetamine
(Tancer and Johanson 2003), self-administration studies in nonhuman subjects suggest that
the reinforcing effects of MDMA are less than those of amphetamine-like stimulants
(Beardsley et al. 1986; Fantegrossi et al. 2002; Lamb and Griffiths 1987; Lile et al. 2005;
Wang and Woolverton 2007). This pattern of data may represent species differences in
MDMA effects or may simply be due to methodological differences in assays designed for
rodents, nonhuman primates, and human subjects.
The studies presently reported detail the effects of MDMA on behavior and dopamine
neurochemistry in squirrel monkeys and rhesus monkeys. The major conclusion to be drawn
from the preponderance of these data is that, at the doses tested, MDMA does not function
as a traditional psychostimulant in nonhuman primates. In contrast to cocaine and its tropane
analogs (Kimmel et al. 2007), as well as being distinct from the effects of amphetamine
(Katz et al. 1995), MDMA failed to increase response rate in an assay of schedule-controlled
behavior in squirrel monkeys. Indeed, across the dose range tested, MDMA had no effect
on, or suppressed, responding. Dose–effect curves with traditional psychostimulants using
this assay are biphasic (Howell and Byrd 1995; Howell et al. 1997; Kimmel et al. 2007),
with high doses decreasing response rates via behavioral disruption, but it is important to
note that MDMA never increased responding in the present studies. The lowest dose of
MDMA tested (0.5 mg/kg) did not alter baseline response rates, and the increasing doses
resulted in a monotonic and dose-dependent reduction in schedule-controlled responding.
These results are similar to those previously reported by Frederick et al. (1995), where 1.0
mg/kg MDMA decreased rates of operant responding maintained by food presentation in
rhesus monkeys. Importantly, the behavioral effects of MDMA herein reported appeared to
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be mediated via central 5-HT systems, as pretreatment with both the SSRI, fluoxetine, and
selective 5-HT2A antagonist, M100907, completely reversed the disruptive effects of
MDMA on response rate. In contrast, pretreatment with the selective DAT inhibitor,
RTI-177, was ineffective in attenuating MDMA-induced suppression of behavior. However,
additional studies with more extensive parametric manipulation of drug dose are clearly
warranted. Moreover, under this behavioral paradigm, the role of central 5-HT in the effects
of psychostimulants such as cocaine and GBR12909 is more complex; SSRIs
insurmountably attenuate the behavioral stimulant effects of cocaine, whereas nonselective
5-HT2 antagonists potentiate the behavioral stimulant effects of low to intermediate doses
(Howell and Byrd 1995; Howell et al. 1997).
Doses of MDMA which were at least as high as those which effectively suppressed response
rates had only minor effects on extracellular DA in the squirrel monkey caudate. Again,
contrary to the effects of cocaine and its tropane analogs (Ginsburg et al. 2005), MDMA
administration elicited a much smaller caudate DA response than would be expected for a
psychostimulant. In fact, doses of methamphetamine and RTI-177 that induced significant
stimulant effects in the present study also induced robust increases in extracellular dopamine
in squirrel monkeys (Czoty et al. 2004; Kimmel et al. 2007). However, no more than a
doubling of caudate DA was quantified following MDMA administration, and this effect
returned to baseline levels in under an hour. Moreover, the high dose of MDMA required to
induce modest increases in dopamine caused pronounced behavioral effects resembling a
catatonic state that lasted for several hours. In the rat, the effects of MDMA on extracellular
DA are more robust than we have measured in the monkey (Baumann et al. 2008; Gudelsky
and Yamamoto 2008). Although doses of MDMA and amphetamine can be balanced to
induce equivalent DA overflow in the rat, the influence of pharmacological manipulation of
central serotonin systems on these two drugs differs markedly. For example, pretreatment
with the SSRI fluoxetine blunts the effects of MDMA on extracellular DA, but enhances
amphetamine-induced dopamine release in rat striatum (Gudelsky and Yamamoto 2008). It
seems plausible to speculate that the interaction of MDMA with SERT (Iravani et al. 2000)
in the squirrel monkey may inhibit its effects on extracellular DA.
The rhesus monkey PET experiments presently reported demonstrate a relative lack of
MDMA occupancy of the DAT, a common site of action among both the amphetamine-type
and cocaine-type psychostimulants in nonhuman primates (Ritz and Kuhar 1989). In one
previous study (Frederick et al. 1995), a chronic MDMA dosing regimen involving both
constant and escalating doses administered to rhesus monkeys resulted in both the typical
serotonergic depletions commonly observed, as well as a focused increase in dopamine
concentrations within the caudate nucleus. The subjects undergoing PET procedures in the
present studies had only minimal exposure to MDMA, and thus are not likely to have
undergone either of these neurochemical adaptations. It also seems unlikely that these
present PET results can be explained as a failure to test a sufficiently high dose of MDMA,
because the dose of MDMA here tested (1.5 mg/kg, delivered as an IV bolus) is within the
range of MDMA self-administered by rhesus monkeys over an entire session (Fantegrossi et
al. 2004; Banks et al. 2008) and had significant effects on heart rate during PET
experiments. In contrast, doses of cocaine that maintain maximal self-administration
behavior in rhesus monkeys occupied at least 65% of DAT (Wilcox et al. 2002) and the dose
of RTI-177 that induced significant stimulant effects in the present study resulted in over
70% DAT occupancy (Lindsey et al. 2004) when measured with PET procedures similar to
those in the present study (Wilcox et al., 2002). Finally, the in vitro affinity of MDMA for
the DAT is low in both competition binding assays at human cloned transporters (Ki>10,000
nM, NIMH Psychoactive Drug Screening Program—Ki determinations were generously
provided by the National Institute of Mental Health's Psychoactive Drug Screening Program,
Contract # NO1MH32004 (NIMH PDSP). The NIMH PDSP is Directed by Bryan L. Roth
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MD, PhD at the University of North Carolina at Chapel Hill and Project Officer Jamie
Driscol at NIMH, Bethesda MD, USA. For experimental details please refer to the PDSP
web site http://pdsp.med.unc.edu/ and click on "Binding Assay" or "Functional Assay" on
the menu bar.) and functional assays in rat caudate (EC50~278 nM, Setola et al. 2003). To
our knowledge, analogous studies have not been performed using rhesus monkey tissue.
In summary, the chemical structure of MDMA is psychostimulant-like, and MDMA bears
numerous behavioral and neurochemical similarities to amphetamine-type and cocaine-type
stimulants in rodents. Nevertheless, MDMA failed to induce a behavioral stimulant effect in
squirrel monkeys in an assay of schedule-controlled behavior, had only minor effects on
caudate DA neurochemistry in squirrel monkeys, and exhibited very low occupancy at DAT
in the rhesus monkey. Importantly, the disruptive effects of MDMA on response rates in
squirrel monkeys were completely abolished by pretreatment with fluoxetine and M100907,
suggesting that these behavioral effects are dependent on central 5-HT in general, and 5-
HT2A receptors in particular. More mechanistic studies regarding the apparent lack of
stimulant-like effects of MDMA in nonhuman primates are warranted.
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a Effects of saline (square), 0.3 mg/kg METH (circle), or various doses of MDMA
(diamonds) on behavior maintained by a fixed-interval schedule of stimulus termination. b
Effects of saline (square), 3.0 mg/kg fluoxetine (inverted triangle), or various doses of
M100907 (triangles) on behavior maintained by a fixed-interval schedule of stimulus
termination. Each point represents the mean ± SEM (n=4 squirrel monkeys). Abscissae:
injection condition. Ordinates: response rate (per second) converted to percent of control.
Asterisks indicate significant differences from saline control
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Effects of 1.5 mg/kg MDMA alone (diamond), or following pretreatment with 3.0 mg/kg
fluoxetine (inverted triangle) or various doses of M100907 (triangles) on behavior
maintained by a fixed-interval schedule of stimulus termination. Each point represents the
mean ± SEM (n=4 squirrel monkeys). Abscissa and ordinate as described in Fig. 1. Asterisks
indicate significant differences from saline control, while bull’s eyes represent significant
differences from MDMA alone
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a Within-session analysis of behavior maintained by a fixed-interval schedule of stimulus
termination following injection with 1.5 mg/kg MDMA alone (filled diamonds) or the
combination of 3.0 mg/kg fluoxetine and MDMA (open diamonds). b Within-session
analysis of behavior maintained by a fixed-interval schedule of stimulus termination
following injection with 1.5 mg/kg MDMA alone (filled diamonds) or the combination of
0.3 mg/kg M100907 and MDMA (open diamonds). c Within-session analysis of behavior
maintained by a fixed-interval schedule of stimulus termination following injection with 1.5
mg/kg MDMA alone (filled diamonds), 0.1 mg/kg RTI-177 alone (open circles) or the
combination of 0.1 mg/kg RTI-177 and MDMA (open diamonds). Each point represents the
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mean ± SEM (n=4 squirrel monkeys). Abscissae: successive 5-min components of the
stimulus termination session. Ordinates: response rate (per second) converted to percent of
control
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Effects of 1.5 mg/kg (top) or 3.0 mg/kg (bottom) MDMA on extracellular dopamine levels
within the caudate nucleus of squirrel monkeys s-165 (left) and s-175 (right). Abscissae:
time (minutes) relative to injection of MDMA. Ordinates: extracellular dopamine
(nanomolar), converted to percent of baseline
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Effects of 1.5 mg/kg MDMA on heart rate (left) and rectal temperature (right). Each point
represents the mean ± SEM (n=3 rhesus monkeys). Abscissae: time (minutes) relative to
injection of MDMA. Ordinates: heart rate (beats per minute, left) or rectal temperature (°C,
right), reported as a change from baseline
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Table 1
Individual and mean (±SEM) DAT occupancy in caudate and putamen by 1.5 mg/kg MDMA, administered IV







Occupancy was calculated as 1−([k3b/k4]/[k3a/k4])
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